Lapeyrere 2012 Full journal France KRAS mutation Retrospective 302 analyses Jan 2009 Not specified FFPE archival TATO article testing in CRC study of KRAS March 2009 tissue used analysis management in KRAS mutation testing laboratories (Acquitaine); Full journal KRAS mutation Review of Collected for High resolution Reviewed Chretien 2013 France 674 samples Test failures article testing in mCRC analysis of assessment melting; FFPE tissues; TATo tissues by between Jan allelic mainly primary single testing 2008 – Dec discrimination tissue centre for 2009 PCR routine testing Lievre 2013; Full journal France KRAS mutation Observational 538 cases/ 433 Tests Mostly Testing was TATO article; testing in mCRC retrospective test requests requested sequencing; mainly (86.1%) Artu 2012; TATRS Conference study of initial during a pyrosequencing; on the primary Ducreux 2011 TATRR abstract management of period in SNaPshot; allelic tumour tissue; Test failure mCRC in 160 discrimination; 14.5% of 2011- Flash-KRAS Biomarker hospital centres high resolution testing was Apr 2011 study directed melting prior to the treatment diagnosis of management first metastases Scott 2014 Full journal Australia KRAS mutation Audit of routine 3688 cases (TAT Tests Various: Sanger ~25% from TATO; article testing in mCRC KRAS testing in available for 2531 requested direct (3 sites); biopsy; 75% TATRS; by 9 major cases [4 of the 9 between Sept pyrosequencing surgically TATRR; NATA testing facilities]) 2011-Oct 2013 (2 sites); single resected Proportion of accredited nucleotide base tissue from cases with a molecular extension using FFPE blocks given TATO; pathology Sequenom of the primary service Massarray (2 tissue (i.e., providers sites); Sanger 75% archive sequencing, then tissue SNaPshot (1site); HRM then Sanger
Lapeyrere 2012 Full journal article France KRAS mutation testing in CRC Retrospective study of KRAS analysis management in KRAS mutation testing laboratories (Acquitaine); 302 analyses Jan 2009 2009 Not specified FFPE archival tissue used TATO Chretien 2013 Full journal article France KRAS mutation testing in mCRC Review of analysis of tissues by single testing centre for routine testing 674 samples Collected for assessment between Jan 2008 – Dec 2009 High resolution melting; allelic discrimination PCR Reviewed FFPE tissues; mainly primary tissue Test failures TATo Lievre 2013; Artu 2012; Ducreux 2011 Flash-KRAS study Full journal article; Conference abstract France KRAS mutation testing in mCRC Observational retrospective study of initial management of mCRC in 160 hospital centres 538 cases/ 433 test requests Tests requested during a period in March 2011 Mostly sequencing; pyrosequencing; SNaPshot; allelic discrimination; high resolution melting Testing was mainly (86.1%) on the primary tumour tissue; 14.5% of testing was prior to the diagnosis of first metastases TATO TATRS TATRR Test failure Biomarker directed treatment management Scott 2014 Full journal article Australia KRAS mutation testing in mCRC Audit of routine KRAS testing in by 9 major NATA accredited molecular pathology service providers 3688 cases (TAT available for 2531 cases [4 of the 9 testing facilities]) Tests requested between Sept 2011-Oct 2013 Various: Sanger direct (3 sites); pyrosequencing (2 sites); single nucleotide base extension using Sequenom Massarray (2 sites); Sanger sequencing, then SNaPshot (1site); HRM then Sanger ~25% from biopsy; 75% surgically resected tissue from FFPE blocks of the primary tissue (i.e., 75% archive tissue TATO; TATRS; TATRR; Proportion of cases with a given TATO; 2011- Apr
1331-Contracted_Assessment_Report-accessible.docx